Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Yale University National Alliance for Research on Schizophrenia and Depression |
---|---|
Information provided by: | Yale University |
ClinicalTrials.gov Identifier: | NCT00463879 |
The purpose of this study is to determine the acute effects of the nicotinic receptor allosteric modulator galantamine (0, 4 and 8 mg) on neurocognitive function in schizophrenic smokers (n=20) versus schizophrenic nonsmokers (n=10) in an outpatient human laboratory setting.
Condition | Intervention | Phase |
---|---|---|
Schizophrenia |
Drug: Galantamine |
Phase II Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Galantamine for Cognitive Deficits in Schizophrenia |
Enrollment: | 21 |
Study Start Date: | September 2005 |
Study Completion Date: | September 2007 |
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
-
Schizophrenic smokers (n=20) and schizophrenic nonsmokers (n=10) in these studies (total n=20 subjects) will be:
Exclusion Criteria:
United States, Connecticut | |
Connecticut Mental Health Center, Yale School of Medicine | |
New Haven, Connecticut, United States, 06519 |
Principal Investigator: | Tony P George, M.D. | University of Toronto |
Study ID Numbers: | 0508000458 |
Study First Received: | April 18, 2007 |
Last Updated: | December 11, 2007 |
ClinicalTrials.gov Identifier: | NCT00463879 |
Health Authority: | United States: Institutional Review Board |
Schizophrenia Cognition Smoking |
Galantamine Nicotine Cognitive Deficits |
Nicotine polacrilex Schizophrenia Smoking Galantamine |
Nicotine Mental Disorders Psychotic Disorders Schizophrenia and Disorders with Psychotic Features |
Parasympathomimetics Nootropic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Enzyme Inhibitors Cholinergic Agents |
Pharmacologic Actions Cholinesterase Inhibitors Autonomic Agents Therapeutic Uses Peripheral Nervous System Agents Central Nervous System Agents |